Pfizer announced on Thursday that it is progressing with the development of a once-daily weight loss pill, which the company expects to be competitive in the GLP-1 market. Meanwhile, the U.S. Food and Drug Administration (FDA) did not approve Novo Nordisk’s once-weekly insulin. Additionally, a report from the U.S. Federal Trade Commission (FTC) indicated that pharmacy benefit managers (PBMs) are raising drug prices.
Here are these stories and other significant pharmaceutical news highlights from this week.